Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605475 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT00605475 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 231 participants.
The verdict
NCT00605475, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose tolerance test (OGTT).
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605475
The ClinicalTrials.gov registry entry for NCT00605475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00605475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605475 about?
NCT00605475 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes". The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose tolerance test (OGTT).
What is the current status of trial NCT00605475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2007-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00605475?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Canakinumab (DRUG).
Who is sponsoring clinical trial NCT00605475?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.